Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

Joseph R. Wagner, McClellan M. Walther, W. Marston Linehan, Donald E. White, Steven A. Rosenberg, James C. Yang

Research output: Contribution to journalArticle

Abstract

Purpose: We assessed morbidity, response and survival in patients with metastatic renal carcinoma treated with high dose intravenous interleukin-2 (IL-2) based immunotherapy with the primary renal tumor in place. Materials and Methods: We retrospectively analyzed the records of patients with metastatic renal carcinoma and the primary kidney tumor in situ who were- treated at the surgery branch of the National Cancer Institute. Of the patients 607 were treated with IL-2 based therapy. Patient age, sex, sites of extrarenal disease, morbidity, and response and survival rates were examined. Results: From 1986 to 1996, 51 patients with the majority of disease at extrarenal sites were treated with the primary tumor in place. Treatment involved IL-2 based regimens, reflecting the evolution of immunotherapy at the National Institutes of Health. When evaluating only extrarenal sites, response was complete in i and partial in 2 of the 51 cases (6%). No responses were noted in the primary renal tumor. Three patients with responses at extrarenal sites underwent nephrectomy. The duration of response in these 3 cases was greater than 88, 11 and 4 months, respectively. Median survival in all 51 patients was 13 months (range 1 to 86). Conclusions: Select patients may be treated with IL-2 based immunotherapy with the primary renal tumors in place with morbidity. A randomized study is needed to assess the role of cytoreductive nephrectomy for treating metastatic renal cell carcinoma.

Original languageEnglish (US)
Pages (from-to)43-45
Number of pages3
JournalJournal of Urology
Volume162
Issue number1
DOIs
StatePublished - Jul 1999
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Kidney
Neoplasms
Morbidity
Nephrectomy
Carcinoma
Survival
National Cancer Institute (U.S.)
National Institutes of Health (U.S.)
Survival Rate
Therapeutics

Keywords

  • Carcinoma, renal cell
  • Interleukin-2
  • Kidney
  • Kidney neoplasms
  • Neoplasm metastasis

ASJC Scopus subject areas

  • Urology

Cite this

Wagner, J. R., Walther, M. M., Linehan, W. M., White, D. E., Rosenberg, S. A., & Yang, J. C. (1999). Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. Journal of Urology, 162(1), 43-45. https://doi.org/10.1097/00005392-199907000-00011

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. / Wagner, Joseph R.; Walther, McClellan M.; Linehan, W. Marston; White, Donald E.; Rosenberg, Steven A.; Yang, James C.

In: Journal of Urology, Vol. 162, No. 1, 07.1999, p. 43-45.

Research output: Contribution to journalArticle

Wagner, JR, Walther, MM, Linehan, WM, White, DE, Rosenberg, SA & Yang, JC 1999, 'Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place', Journal of Urology, vol. 162, no. 1, pp. 43-45. https://doi.org/10.1097/00005392-199907000-00011
Wagner, Joseph R. ; Walther, McClellan M. ; Linehan, W. Marston ; White, Donald E. ; Rosenberg, Steven A. ; Yang, James C. / Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. In: Journal of Urology. 1999 ; Vol. 162, No. 1. pp. 43-45.
@article{4eaa7e7e8ea94fe082e8406e2d305569,
title = "Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place",
abstract = "Purpose: We assessed morbidity, response and survival in patients with metastatic renal carcinoma treated with high dose intravenous interleukin-2 (IL-2) based immunotherapy with the primary renal tumor in place. Materials and Methods: We retrospectively analyzed the records of patients with metastatic renal carcinoma and the primary kidney tumor in situ who were- treated at the surgery branch of the National Cancer Institute. Of the patients 607 were treated with IL-2 based therapy. Patient age, sex, sites of extrarenal disease, morbidity, and response and survival rates were examined. Results: From 1986 to 1996, 51 patients with the majority of disease at extrarenal sites were treated with the primary tumor in place. Treatment involved IL-2 based regimens, reflecting the evolution of immunotherapy at the National Institutes of Health. When evaluating only extrarenal sites, response was complete in i and partial in 2 of the 51 cases (6{\%}). No responses were noted in the primary renal tumor. Three patients with responses at extrarenal sites underwent nephrectomy. The duration of response in these 3 cases was greater than 88, 11 and 4 months, respectively. Median survival in all 51 patients was 13 months (range 1 to 86). Conclusions: Select patients may be treated with IL-2 based immunotherapy with the primary renal tumors in place with morbidity. A randomized study is needed to assess the role of cytoreductive nephrectomy for treating metastatic renal cell carcinoma.",
keywords = "Carcinoma, renal cell, Interleukin-2, Kidney, Kidney neoplasms, Neoplasm metastasis",
author = "Wagner, {Joseph R.} and Walther, {McClellan M.} and Linehan, {W. Marston} and White, {Donald E.} and Rosenberg, {Steven A.} and Yang, {James C.}",
year = "1999",
month = "7",
doi = "10.1097/00005392-199907000-00011",
language = "English (US)",
volume = "162",
pages = "43--45",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

AU - Wagner, Joseph R.

AU - Walther, McClellan M.

AU - Linehan, W. Marston

AU - White, Donald E.

AU - Rosenberg, Steven A.

AU - Yang, James C.

PY - 1999/7

Y1 - 1999/7

N2 - Purpose: We assessed morbidity, response and survival in patients with metastatic renal carcinoma treated with high dose intravenous interleukin-2 (IL-2) based immunotherapy with the primary renal tumor in place. Materials and Methods: We retrospectively analyzed the records of patients with metastatic renal carcinoma and the primary kidney tumor in situ who were- treated at the surgery branch of the National Cancer Institute. Of the patients 607 were treated with IL-2 based therapy. Patient age, sex, sites of extrarenal disease, morbidity, and response and survival rates were examined. Results: From 1986 to 1996, 51 patients with the majority of disease at extrarenal sites were treated with the primary tumor in place. Treatment involved IL-2 based regimens, reflecting the evolution of immunotherapy at the National Institutes of Health. When evaluating only extrarenal sites, response was complete in i and partial in 2 of the 51 cases (6%). No responses were noted in the primary renal tumor. Three patients with responses at extrarenal sites underwent nephrectomy. The duration of response in these 3 cases was greater than 88, 11 and 4 months, respectively. Median survival in all 51 patients was 13 months (range 1 to 86). Conclusions: Select patients may be treated with IL-2 based immunotherapy with the primary renal tumors in place with morbidity. A randomized study is needed to assess the role of cytoreductive nephrectomy for treating metastatic renal cell carcinoma.

AB - Purpose: We assessed morbidity, response and survival in patients with metastatic renal carcinoma treated with high dose intravenous interleukin-2 (IL-2) based immunotherapy with the primary renal tumor in place. Materials and Methods: We retrospectively analyzed the records of patients with metastatic renal carcinoma and the primary kidney tumor in situ who were- treated at the surgery branch of the National Cancer Institute. Of the patients 607 were treated with IL-2 based therapy. Patient age, sex, sites of extrarenal disease, morbidity, and response and survival rates were examined. Results: From 1986 to 1996, 51 patients with the majority of disease at extrarenal sites were treated with the primary tumor in place. Treatment involved IL-2 based regimens, reflecting the evolution of immunotherapy at the National Institutes of Health. When evaluating only extrarenal sites, response was complete in i and partial in 2 of the 51 cases (6%). No responses were noted in the primary renal tumor. Three patients with responses at extrarenal sites underwent nephrectomy. The duration of response in these 3 cases was greater than 88, 11 and 4 months, respectively. Median survival in all 51 patients was 13 months (range 1 to 86). Conclusions: Select patients may be treated with IL-2 based immunotherapy with the primary renal tumors in place with morbidity. A randomized study is needed to assess the role of cytoreductive nephrectomy for treating metastatic renal cell carcinoma.

KW - Carcinoma, renal cell

KW - Interleukin-2

KW - Kidney

KW - Kidney neoplasms

KW - Neoplasm metastasis

UR - http://www.scopus.com/inward/record.url?scp=0032883614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032883614&partnerID=8YFLogxK

U2 - 10.1097/00005392-199907000-00011

DO - 10.1097/00005392-199907000-00011

M3 - Article

C2 - 10379736

AN - SCOPUS:0032883614

VL - 162

SP - 43

EP - 45

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -